Health Trials

HR+ HER2- Breast Cancer

2

Review clinical trials related to HR+ HER2- Breast Cancer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

The study is a Phase 1b/2, multi-center, open-label, dose escalation trial evaluating the safety and preliminary efficacy of sapanisertib and serabelisib (PIKTOR) with fulvestrant and/or other anticancer therapies in participants with HR+/HER2- advanced/metastatic breast cancer.

Participants needed: 32
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Faeth TherapeuticsUpdated: Jul 2, 2026Locations: 7
Eligibility criteria

Histologically confirmed diagnosis of HR+/HER2- breast cancer. [+5]

Participants with triple-negative breast cancer. [+11]

Read more
Status: Recruiting

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tumors with CCNE1 amplification). Main questions to answer include: * What is the recommended dose for expansion and/or Phase 2, for both monotherapy and in combination with ET * What medical issues/symptoms do participants experience when taking NKT5097 as monotherapy as well as in combination with ET

Participants needed: 361
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: NiKang Therapeutics, Inc.Updated: Jun 26, 2026Locations: 18
Eligibility criteria

Able to provide written informed consent [+12]

Advanced solid tumor that is a candidate for curative treatment [+10]

Read more